Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Inflammation and the immune system

Topic: Brain proteins, microglia and lab models

Plain-language summary

The analysis included 26 original articles describing (1050 rodents) with AD-like symptoms. Rodents treated with cannabinoid agonists showed significant reductions in escape latency (standard mean difference [SMD] = -1.26; 95% confidence interval [CI]: -1.77 to -0.76, p p p = 0.006) was observed in the endocannabinoid-treated group compared to the control group. Trends were observed toward neuroprotection, as represented by decreased levels of glial cell markers including glial fibrillary acid protein (SMD = -1.47; 95% CI: -2.56 to -0.38, p = 0.008) and Iba1 (SMD = -1.67; 95% CI: -2.56 to -0.79, p = 0.0002). Studies on the wild-type mice demonstrated significantly decreased levels of pro-inflammatory markers TNF-α, IL-1, and IL-6 (SMD = -2.28; 95% CI: -3.15 to -1.41, p = 0.00001). Despite the non-significant decrease in pro-inflammatory marker levels in transgenic mice (SMD = -0.47; 95% CI: -1.03 to 0.08, p = 0.09), the result favored the endocannabinoid-treated group over the control group. The revised data suggested that endocannabinoid stimulation promotes cognitive function via modulation of glial cells by decreasing pro-inflammatory markers in AD-like rodent models. Thus, cannabinoid agents may be required to modulate the downstream chain of effect to enhance cognitive stability against concurrent neuroinflammation in AD. Population-based studies and well-designed clinical trials are required to characterize the acceptability and real-world effectiveness of cannabinoid agents. Systematic Review Registration: [https://inplasy.com/inplasy-2022-8-0094/], identifier [Inplasy Protocol 3770].

What this study adds

Evidence grade: High

This is a pooled review of 26 participants. Across 26 studies of 1050 rodents with Alzheimer-like symptoms, animals given cannabinoid agonists did better on a learning task (shorter escape latency) and had lower levels of glial cell markers such as glial fibrillary acid protein and Iba1. Inflammatory markers fell clearly in wild-type mice but not significantly in transgenic mice.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kamaruzzaman, M. A., Romli, M. H., Abas, R., Vidyadaran, S., Hidayat Baharuldin, M. T., Nasaruddin, M. L., et al. (2023). Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2023.1053680

Vancouver

Kamaruzzaman MA, Romli MH, Abas R, Vidyadaran S, Hidayat Baharuldin MT, Nasaruddin ML, et al. Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies. Frontiers in pharmacology. 2023. doi:10.3389/fphar.2023.1053680. PMID: 36959856.

BibTeX

@article{kamaruzzaman2023-36959856,
  author  = {Kamaruzzaman, M. A. and Romli, M. H. and Abas, R. and Vidyadaran, S. and Hidayat Baharuldin, M. T. and Nasaruddin, M. L. and Thirupathirao, V. and Sura, S. and others},
  title   = {{Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies}},
  journal = {Frontiers in pharmacology},
  year    = {2023},
  doi     = {10.3389/fphar.2023.1053680},
  pmid    = {36959856},
  url     = {https://doi.org/10.3389/fphar.2023.1053680}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Across 26 studies of 1050 rodents with Alzheimer-like symptoms, animals given cannabinoid agonists did better on a learning task (shorter escape latency) and had lower levels of glial cell markers such as glial fibrillary acid protein and Iba1. Inflammatory markers fell clearly in wild-type mice but not significantly in transgenic mice. Since these are animal results, the authors call for population studies and well-designed clinical trials to see whether cannabinoid agents help people.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 61 of 100.61 of 100 points earned39 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in pharmacology)
Journal's citation record 2 / 4 Frontiers in Pharmacology: journal h-index 242 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 1 / 4 26 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 3 / 7 Cited 22 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.4 citations a year over 5 year(s) since 2023
Impact for its field and year 2 / 6 Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Mohamad Aris Mohd Moklas: h-index 27 (OpenAlex, whole career)
Institution's track record 1 / 3 Monash University: institution h-index 1,146 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 8 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 36959856)
Free to read 2 / 2 Free to read
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Inflammation and the immune system from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →